CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 92 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $636,000 | -10.0% | 5,367 | -10.3% | 0.00% | -33.3% |
| Q4 2020 | $707,000 | +2.3% | 5,986 | -3.7% | 0.00% | 0.0% |
| Q3 2020 | $691,000 | +10.0% | 6,218 | +1.1% | 0.00% | 0.0% |
| Q2 2020 | $628,000 | +9.8% | 6,150 | +16.0% | 0.00% | -25.0% |
| Q1 2020 | $572,000 | -41.0% | 5,300 | -36.4% | 0.00% | 0.0% |
| Q4 2019 | $970,000 | -18.2% | 8,331 | -19.6% | 0.00% | -42.9% |
| Q3 2019 | $1,186,000 | +9.5% | 10,358 | -8.9% | 0.01% | +16.7% |
| Q2 2019 | $1,083,000 | -11.2% | 11,365 | -15.0% | 0.01% | -14.3% |
| Q1 2019 | $1,220,000 | +20.4% | 13,372 | +0.2% | 0.01% | 0.0% |
| Q4 2018 | $1,013,000 | -16.7% | 13,340 | -12.2% | 0.01% | -12.5% |
| Q3 2018 | $1,216,000 | -12.1% | 15,197 | +9.1% | 0.01% | -11.1% |
| Q2 2018 | $1,383,000 | +33.8% | 13,925 | +9.1% | 0.01% | +28.6% |
| Q1 2018 | $1,034,000 | -11.8% | 12,765 | -14.2% | 0.01% | -12.5% |
| Q4 2017 | $1,172,000 | -17.2% | 14,875 | -3.0% | 0.01% | -38.5% |
| Q3 2017 | $1,416,000 | – | 15,341 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maso Capital Partners Ltd | 164,500 | $15,011,000 | 10.32% |
| HHLR ADVISORS, LTD. | 2,751,200 | $251,047,000 | 6.99% |
| Dalton Investments, Inc. | 113,851 | $10,389,000 | 4.54% |
| Point72 Hong Kong Ltd | 115,939 | $10,579,000 | 4.17% |
| York Capital Management Global Advisors, LLC | 991,233 | $90,450,000 | 4.05% |
| RUDMAN ERROL M | 58,000 | $5,293,000 | 3.57% |
| Greenwoods Asset Management Ltd | 479,580 | $43,762,000 | 2.69% |
| Parametrica Management Ltd | 3,663 | $334,000 | 0.71% |
| Temasek Holdings (Private) Ltd | 990,000 | $90,338,000 | 0.62% |
| Athos Capital Ltd | 8,290 | $756,000 | 0.49% |